Ipsen renews research accord with Salk Institute and partners with Gustave Roussy

French drugmaker Ipsen (Euronext: IPN) and the Salk Institute for Biological Studies are renewing the Ipsen Life Sciences Program at the Institute. The mission of the partnership is to advance knowledge in the field of proliferative and degenerative diseases through fundamental and applied biology research.

The Ipsen Life Sciences Program led by the Salk Institute’s Inder Verma, Irwin and Joan Jacobs Chair in Exemplary Science, will for a period of three years, sponsor four research programs through targeted and innovation grants. Ipsen will provide funding for targeted research programs carried out at the Salk Institute by researchers on novel therapeutic concepts for the treatment of pituitary adenomas, cancer and neurodegenerative diseases. Innovation grants will fund the exploration of advanced scientific concepts.

Over the last three years, the partnership between the Salk Institute and Ipsen has delivered significant scientific advances in the cancer field such as the development of biological models mimicking human cancerous processes as well as identification of specific cells driving tumor growth. In addition, the development of stem cells technology has opened up promising new vistas of research in neurodegenerative diseases.